Comparison of Phase I/II trials regarding antigen-specific versus non-specific anticancer immunotherapies

Antigen-specific immunotherapy targets particular tumour associated antigens in order to address and eradicate solely tumour-marker defined cancer cells. In contrast, non-specific agents generally stimulate the immune system by for example reversal of immune suppression, or activation of innate immunity for a better anti-cancer immune response. We investigated whether differences among these two classes are reflected in patient selection, objectives and results of Phase I/II studies.

Share this: